Private company

Virpax Pharmaceuticals, Inc.

American pharmaceutical preparations company based in Berwyn1

In its 2025 annual report the company says: “We are a preclinical stage biopharmaceutical company with a limited operating history.”9

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBerwyn, Pennsylvania1
  • Incorporated inDE2
  • Business address1055 Westlakes Drive, Suite 300, Berwyn, Pa 193122
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3456-$12.1M in 2024+188% since 2020
-$30.0M-$20.0M-$10.0M02020: -$4.2M-$4.2M20202021: -$12.0M-$12.0M2021+187%2022: -$21.8M-$21.8M2022+82%2023: -$15.7M-$15.7M2023−28%2024: -$12.1M-$12.1M2024−23%
Net income3456-$12.1M in 2024+178% since 2020
-$30.0M-$20.0M-$10.0M02020: -$4.3M-$4.3M20202021: -$12.1M-$12.1M2021+178%2022: -$21.7M-$21.7M2022+80%2023: -$15.2M-$15.2M2023−30%2024: -$12.1M-$12.1M2024−21%
Fiscal year2019202020212022202320242025
Research and development$1.3M3$4.8M4$10.8M5$5.1M6$5.8M6
Operating expenses$12.0M4$21.8M5$15.7M6$12.1M6
Operating income-$4.2M3-$12.0M4-$21.8M5-$15.7M6-$12.1M6
Interest$147.9K3$92.8K4
Income before tax-$12.1M4-$21.7M5-$15.2M5
Net income-$4.3M3-$12.1M4-$21.7M5-$15.2M6-$12.1M6
Earnings per share-$1.403-$1.814-$18.495-$12.976-$2.846
Earnings per share (diluted)-$1.814-$18.495-$12.976-$2.846
Shares (weighted, basic)6.7M shares41.2M shares51.2M shares64.3M shares6
Shares (weighted, diluted)6.7M shares41.2M shares51.2M shares64.3M shares6

Compare Virpax Pharmaceuticals, Inc. with another company

Corporate structure

Virpax Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Virpax Pharmaceuticals, Inc.

  • INTRACOASTAL CAPITAL, LLC Filed SC 13G on Virpax Pharmaceuticals, Inc., latest May 23, 2024
  • SABBY MANAGEMENT, LLC Filed SC 13G/A on Virpax Pharmaceuticals, Inc., latest Jan 2, 2024 (3 filings since Jan 4, 2022)
  • Anthony P. Mack Filed SC 13G/A on Virpax Pharmaceuticals, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Kepos Capital LP Filed SC 13G/A on Virpax Pharmaceuticals, Inc., latest Jan 26, 2023 (2 filings since Feb 4, 2022)
  • CVI Investments, Inc. Filed SC 13G/A on Virpax Pharmaceuticals, Inc., latest Feb 14, 2022
  • Virpax Pharmaceuticals, Inc. Berwyn, Pennsylvania

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Virpax Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our principal address is 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate alternative space would be readily available on commercially reasonable terms.

Item 2 of the 10-K filed Mar 3, 2025.9

Leadership

Who has led Virpax Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Anthony P. Mack2021–2023
  2. Gerald W. Bruce2024

Chief financial officer

  1. Christopher Michael Chipman2021–2023
  2. Vinay Shah2023–2024
  3. Usama Chaudhry2025
2025
Board members and other officers (18)

Timeline

  1. Apr 3, 20258-K Listing notice or transfer; Executive or director change31
  2. Apr 3, 20258-K Listing notice or transfer; Executive or director change32
  3. Mar 21, 20258-K Bylaws or fiscal year changed33
  4. Feb 6, 20258-K Executive or director change34
  5. Feb 4, 20258-K Executive or director change35
  6. Jan 30, 20258-K Entered a material agreement; Regulation FD disclosure36
  7. Jan 15, 20258-K Shareholder vote37
  8. Jan 7, 20258-K Other events38
  9. Dec 30, 20248-K Executive or director change39
  10. Dec 18, 20248-K Executive or director change40
  11. Dec 13, 20248-K Executive or director change41
  12. Nov 29, 20248-K Bylaws or fiscal year changed42
  13. Jan 31, 2024New chief executive Gerald W. Bruce becomes CEO10
  14. Feb 16, 2021New chief executive Anthony P. Mack becomes CEO11

Calendar

When it reported results

  1. Aug 13, 2024Reported quarterly or annual results43
  2. May 13, 2024Reported quarterly or annual results44
  3. Mar 26, 2024Reported quarterly or annual results45
  4. Nov 16, 2023Reported quarterly or annual results46
  5. Aug 14, 2023Reported quarterly or annual results47
  6. May 12, 2023Reported quarterly or annual results48
  7. Mar 22, 2023Reported quarterly or annual results49
  8. Nov 9, 2022Reported quarterly or annual results50

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

206 filings to the SEC since October 2021: 6 annual reports, 10 quarterly reports, 67 major events, 53 insider forms, 9 large holders, 1 private raises, 60 other. The latest 20:

  1. Apr 3, 20258-K/A EDGAR
  2. Apr 3, 20258-K EDGAR
  3. Mar 25, 2025S-1/A EDGAR
  4. Mar 21, 20258-K EDGAR
  5. Mar 17, 2025S-1 EDGAR
  6. Mar 3, 202510-K EDGAR
  7. Feb 6, 20258-K EDGAR
  8. Feb 4, 20258-K EDGAR
  9. Jan 30, 20258-K EDGAR
  10. Jan 28, 2025424B4 EDGAR
  11. Jan 27, 2025EFFECT EDGAR
  12. Jan 22, 2025CORRESP EDGAR
  13. Jan 22, 2025CORRESP EDGAR
  14. Jan 17, 2025S-1/A FORM S-1/A2 EDGAR
  15. Jan 15, 2025S-1/A FORM S-1/A1 EDGAR
  16. Jan 15, 20258-K EDGAR
  17. Jan 8, 20253 EDGAR
  18. Jan 7, 20258-K EDGAR
  19. Jan 6, 20253 EDGAR
  20. Jan 3, 2025UPLOAD EDGAR

The 206 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 24, 2022Sendrow JerroldDirectorBuy4,500$1.29$5.8KForm 4
May 18, 2022Mack Anthony P.Chief Executive OfficerBuy75,750$1.34$101.5KForm 4
May 18, 2022Floyd EricDirectorBuy4,479$1.36$6.1KForm 4
Nov 22, 2021Sendrow JerroldDirectorBuy3,900$3.93$15.3KForm 4
Nov 18, 2021Mack Anthony P.Chief Executive OfficerBuy25,125$3.99$100.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2023Anthony Mack$445.0K$1.2M56
2023Sheila A. Mathias PhDJD$308.0K$498.0K56
2023Christopher Chipman$169.0K$491.0K56
2023Vinay Shah$123.0K$324.0K56
2023Gerald W. Bruce$38.0K$128.0K56
2022Former Chief Executive OfficerChairman$467.0K$784.0K56
2022Former Chief Financial Officer$296.0K$467.0K56

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 5, 2024Raised $2.5 million in a private offering of debt Form D: 1 investor so far Form D

SEC filer profile

How Virpax Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVirpax Pharmaceuticals, Inc.1
  • CIK0001708331
  • Employer ID (EIN)82-15109829
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company9
  • Incorporated inDelaware9
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1055 Westlakes Drive, Suite 300, Berwyn, PA 193121
  • Phone610-727-45971
  • Shares outstanding26,562,581 shares as of Feb 26, 20259
  • Public float$1.5M as of Jun 30, 20249
  • AuditorBush & Associates CPA LLC, Henderson, Nevada PCAOB ID 6797; no auditor attestation of internal control over financial reporting9
  • On EDGAR sinceApr 5, 20181
  • Filings278 in all: 8-K (70), 4 (50), CORRESP (25), 3 (22), S-1/A (14), 10-Q (12), UPLOAD (9), EFFECT (6)1
    All 32 form types

    S-1 (6), SC 13G (6), SC 13G/A (6), 10-K (5), 4/A (5), 424B4 (5), DEF 14A (5), DEFA14A (4), S-8 (4), 10-K/A (2), 8-K/A (2), ARS (2), D (2), DRS (2), FWP (2), POS EX (2), PRE 14A (2), SEC STAFF LETTER (2), 25-NSE (1), 8-A12B (1), CERT (1), NT 10-Q (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2025
    Quarterly report (10-Q) Nov 14, 2024
    Proxy statement (DEF 14A) Dec 9, 2024
    Latest 8-K (8-K) Apr 3, 2025

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.00001 per shareVRPXNasdaq

From the cover page of the 10-K filed Mar 3, 2025 (Section 12(b) of the Exchange Act).9

Risk factors and legal proceedings

The risks Virpax Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 3, 2025: 70 risks under these headings, as written.9

  • Risks Related to Our Financial Position and Need for Additional Capital
  • We are a preclinical stage biopharmaceutical company with a limited operating history.
  • We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.
  • The report of our independent registered public accounting firm for the fiscal years ended December 31, 2024 and 2023 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
  • We will need to spend substantial amounts to advance the clinical development of and launch and commercialize our product candidates.
  • Our business, financial condition and results of operations could be adversely affected by indemnification and other claims related to the damages awarded in our recently settled litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
  • Our ability to further develop our product candidates may be adversely affected by the terms of the Settlement Agreement.
  • The Company and our officers and directors may be subject to various types of litigation, and our insurance may not cover or be sufficient to cover damages related to those claims.
  • We may face challenges in retaining key personnel and maintaining business continuity as a result of recent cost-cutting measures, including salary reductions, which may also affect our product development and timelines.
  • The elimination of our directors and officers insurance may affect retention, expose our directors and officers to personal liability, and impact our financial condition.
The other 59 risks
  • The cancellation of our cybersecurity insurance may expose us to increased financial and operational risks.
  • The recent elimination of directors and officers insurance may negatively impact our ability to retain key personnel and disrupt our business operations.
  • Our arrangements relating to independent contractors may be questioned by the relevant authorities and if such authorities determine that such arrangements constitute employment, we may be liable to make certain back payments and payments of interest and penalties to such authorities.
  • Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval
  • Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.
  • Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.
  • Adverse global conditions, including economic uncertainty, may negatively impact our financial results.
  • Our development activities for Probudur are conducted in Israel. The war in the Middle East, may affect our operations.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our Product Candidates or any other product candidates, our business will be substantially harmed.
  • If we are unable to file for approval of Epoladerm and Probudur under Section 505(b)(2) of the FDCA or if we are required to generate additional data related to safety and efficacy in order to obtain approval under Section 505(b)(2), we may be unable to meet our anticipated development and commercialization timelines.
  • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
  • The resurgence of COVID-19 pandemic could adversely affect our business or another health epidemic or pandemic may have an adverse impact on our business in the future.
  • Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.
  • Interim “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
  • The market opportunities for our Product Candidates, if approved, may be smaller than we anticipate.
  • We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.
  • Even if we obtain FDA approval for our Product Candidates or any other product candidate in the United States, we may never obtain approval for or commercialize our Product Candidates or any other product candidate in any other jurisdiction, which would limit our ability to realize their full market potential.
  • Even if we obtain regulatory approval for our Product Candidates or any product candidate, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties.
  • Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
  • Risks Related to Commercialization
  • We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.
  • The successful commercialization of our Product Candidates and any other product candidate we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
  • Even if our Product Candidates or any product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
  • If we are unable to establish sales, marketing, and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our Product Candidates, if approved.
  • A variety of risks associated with operating internationally could materially adversely affect our business.
  • Risks Related to Our Dependence on Third Parties
  • Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
  • We currently rely on third-party contract manufacturing organizations (“CMOs”) for the production of clinical supply of our Product Candidates and intend to rely on CMOs for the production of commercial supply of our Product Candidates, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.
  • We intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.
  • Risks Related to Healthcare Laws and Other Legal Compliance Matters
  • Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.
  • Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
  • Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.
  • We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.
  • Risks Related to Our Intellectual Property
  • If we fail to comply with our obligations under our existing intellectual property license, we risk losing the rights to our intellectual property.
  • If we are unable to obtain and maintain patent protection for our technology, products, and product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.
  • We may become subject to third parties’ claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our products and product candidates or put our patents and other proprietary rights at risk.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our products and product candidates.
  • Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products and product candidates.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.
  • If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our products, our business may be materially harmed.
  • Intellectual property rights do not address all potential threats to our competitive advantage.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • We may be subject to claims that our employees, consultants, collaborators contractors or advisors have wrongfully used or disclosed confidential information of their former employers or other third parties.
  • Our proprietary information may be lost, or we may suffer security breaches.
  • Risks Related to Our Employees, Managing Our Growth and Our Operations
  • We have experienced turnover in our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.
  • We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.
  • Our business and operations would suffer in the event of system failures.
  • We are increasingly dependent on information technology, and our systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
  • Risks Related to Our Common Stock
  • The market price of our common stock has been volatile and can fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
  • We could be subject to securities class action litigation.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.
  • Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
  • We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.
  • We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.
  • Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.
  • Our certificate of incorporation, as amended, designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
  • Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our common stock.

Legal proceedings

On March 12, 2021, the Company and its former Chief Executive Officer, Anthony P. Mack (together, the “Defendants”), were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware captioned Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. v. Anthony Mack and Virpax Pharmaceuticals, Inc., Case No. 2021-0210-PAF (the “Action”). In the Complaint, Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021, Plaintiffs filed an Amended Complaint asserting the same three causes of action. On September 28, 2021, Plaintiffs filed a Second Amended Complaint asserting the same three causes of action as the prior complaints, as well as claims in which Plaintiffs alleged (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On April 1, 2022, Plaintiffs filed a Third Amended Complaint. The Third Amended Complaint asserts the same causes of action as the Second Amended Complaint, as well as claims for (i) misappropriation of trade secrets by Defendants under Delaware law, and (ii) misappropriation of trade secrets by Defendants under California law. On April 18, 2022, Defendants filed answers to the Third Amended Complaint.

The opening of Item 3, Legal Proceedings.9

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56